Cellectar BioSciences, Inc.
(NASDAQ : CLRB)

( )
CLRB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.98%81.590.9%$637.74m
CELGCelgene Corporation
-0.88%135.961.1%$563.57m
AMGNAmgen Inc.
-1.16%184.121.1%$451.54m
BIIBBiogen Inc.
-0.63%342.421.2%$397.97m
REGNRegeneron Pharmaceuticals, Inc.
0.36%440.942.7%$313.46m
ALNYAlnylam Pharmaceuticals, Inc
-1.63%115.6310.7%$252.14m
VRTXVertex Pharmaceuticals Incorporated
-0.10%154.601.9%$218.27m
INCYIncyte Corporation
-0.76%114.272.5%$205.56m
ALXNAlexion Pharmaceuticals, Inc.
0.16%140.461.9%$180.37m
EXELExelixis, Inc.
-0.25%27.466.5%$136.95m
ILMNIllumina, Inc.
-0.21%205.183.5%$132.63m
BLUEBluebird Bio, Inc.
0.25%139.4517.3%$114.79m
BMRNBioMarin Pharmaceutical Inc.
-0.55%88.134.4%$113.12m
SRPTSarepta Therapeutics, Inc.
-1.36%50.7216.9%$105.98m
CLVSClovis Oncology, Inc.
-2.48%76.7716.5%$102.15m

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on April 11, 2011 and is headquartered in Madison, WI.